Doug Saffran

Douglas C. Saffran, Ph.D.

Vice President, Pharmacology

Doug joined Kronos Bio in 2018 after having worked at several companies on drug development programs for oncology and autoimmune diseases. Prior to Kronos Bio, Doug led Pharmacology groups in oncology research at companies including Warp Drive Bio, Amgen, and Agensys, evaluating targeted therapies including small molecules, antibodies, and antibody-drug conjugates. Doug received a Ph.D. from the department of Microbiology and Immunology at the University of Western Ontario and completed post-doctoral training in the lab of Dr. Owen N. Witte at the Howard Hughes Medical Institute at UCLA. While at UCLA Doug was part of a team that discovered Bruton’s tyrosine kinase (BTK) and characterized the function and behavior of specific mutations in the BTK gene present in B cells from patients with X-linked agammaglobulinemia (XLA).